Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: Efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial

Archives of Dermatology

Volumn 147, Issue 4, 2011, Pages 429-436

  Leonardi, Craig ^a   Langley, Richard G ^b   Papp, Kim ^c   Tyring, Stephen K ^d   Wasel, Norman ^e   Vender, Ronald ^f   Unnebrink, Kristina ^g   Gupta, Shiraz R ^h   Valdecantos, Wendell C ^h   Bagel, Jerry ⁱ  

^a Central Dermatology   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d UNIVERSITY OF TEXAS   (United States)

^e Stratica Medical Canada   (Canada)

^f Dermatrials Research   (Canada)

^g ABBOTT GMBH AND CO KG   (Germany)

^h ABBOTT LABORATORIES   (United States)

ⁱ Psoriasis Treatment Center of Central New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CLINICAL ASSESSMENT TOOL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; FOOT; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HAND; HUMAN; INJECTION SITE REACTION; LUNG EDEMA; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; PARESTHESIA; PHYSICIAN GLOBAL ASSESSMENT OF HANDS AND OR FEET; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN CANCER; THORAX PAIN; TONGUE SWELLING; TUBERCULOSIS; URTICARIA;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CANADA; DOUBLE-BLIND METHOD; FOOT; HAND; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 79953863873     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.384     Document Type: Article

References (28)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. (Pubitemid 351509656)
2. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024-1031.
3. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl JMed. 1995;332(9):581-588.
4. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82(3):192-195. (Pubitemid 34848394)
5. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. JAmAcad Dermatol. 2003;49(2):271-275. (Pubitemid 36951276)
6. Adişen E, Tekin O, Gülekon A, Gürer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23(7):814-819.
7. Cohen DJ, Scherschun L. Case reports: practical experience with efalizumab in hand and foot psoriasis. J Drugs Dermatol. 2007;6(12):1224-1230.
8. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003;72(5):396-398. (Pubitemid 37550146)
9. Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006;78(3):178-180. (Pubitemid 44484437)
10. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum. 2008;37(4):251-255.
11. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100-108.
12. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52(8):2513-2518. (Pubitemid 41117439)
13. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007;34(7):468-472. (Pubitemid 46956592)
14. Saurat JH, Stingl G, Dubertret L, et al; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
15. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
16. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896-904.
17. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg. 2009;13(1):1-5.
18. Rigopoulos D, Gregoriou S, Lazaridou E. Treatment of nail psoriasis with adalimumab: an open label unblinded study [published online ahead of print October 6, 2009]. J Eur Acad Dermatol Venereol. 2010;24(5):530-534.
19. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009;13(suppl 2):S102-S106.
20. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20(1):60-67. (Pubitemid 46568378)
21. Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology. 2009;219(4):353-356.
22. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(suppl 1):15-21.
23. Koo JYM, Lebwohl MG, Lee CS, eds. Mild-to-Moderate Psoriasis. New York, NY: Informa Healthcare USA, Inc; 2006.
24. Leonardi CL, Sobell JM, Sofen H, Krell J. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot psoriasis [abstract]. J Am Acad Dermatol. 2007;56(2):AB48.
25. Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol. 2008;7(10):940-946.
26. Bissonnette R, Poulin Y, Guenther L, Lynde C, Bolduc C, Nigen S. Treatment of palmoplantar psoriasis with infliximab [abstract P1159]. Presented at: European Academy of Dermatology and Venereology Congress; October 7-11, 2009; Berlin, Germany.
27. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25(6):510-518. (Pubitemid 350087596)
28. Guinot C, Latreille J, Perrussel M, Doss N, Dubertret L; French Psoriasis Group. Psoriasis: characterization of six different clinical phenotypes. Exp Dermatol. 2009;18(8):712-719.